DIABLO

The following DIABLO reagents supplied by CUSABIO are manufactured under a strict quality control system. Multiple applications have been validated and solid technical support is offered.

DIABLO Antibodies

DIABLO Antibodies for Homo sapiens (Human)

DIABLO Proteins

DIABLO Proteins for Xenopus laevis (African clawed frog)

DIABLO Proteins for Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)

DIABLO Proteins for Pongo abelii (Sumatran orangutan) (Pongo pygmaeus abelii)

DIABLO Proteins for Homo sapiens (Human)

DIABLO Proteins for Mus musculus (Mouse)

DIABLO Background

Direct inhibitor of apoptosis-binding protein with a low isoelectric point, pI (DIABLO), also known as a second mitochondria-derived activator of caspase (SMAC), is a pro-apoptotic mitochondrial protein. DIABLO/SMAC is normally localized within the mitochondria [1]. It has an N-terminus with a stretch of amino acids characteristic of mitochondrial targeting sequences that are removed from proteins upon import into mitochondria. Following an apoptotic trigger, mitochondria undergo loss of inner mitochondrial membrane potential and subsequent mitochondrial membrane permeabilization (MMP) [2]. The N-terminally processed DIABLO/SMAC is released into the cytosol together with cytochrome c [1][2]. Cytochrome c directly activates the Apaf-1/caspase-9 apoptosome and downstream effector caspases, leading to apoptosis [3]. However, the activity of mature caspases is inhibited by their interaction with the inhibitor of apoptosis proteins (IAPs) [4][5]. DIABLO/SMAC promotes apoptosis by abrogating the inhibitory effect of IAPs through physical interactions [6]. Amino-terminal sequences in DIABLO/SMAC are required for its interaction with IAPs [7][8]. Studies demonstrated that DIABLO/SMAC interacts with the BIR2 and BIR3 domains of XIAP, allowing the release of caspase-3 [9] and caspase 9 [10], respectively. Several studies have shown that overexpression of DIABLO/SMAC sensitizes tumor cells to apoptosis [11][12]. The role of DIABLO/SMAC, therefore, may have significant diagnostic and therapeutic features in carcinogenesis. Furthermore, amino-terminal DIABLO/SMAC derivatives and small molecules that mimic the DIABLO/SMAC function could be a potential therapy for tumors with the expression of IAPs.

[1] Du C, Fang M, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition [J]. Cell. 2000, 102 (1): 33-42.
[2] X. Wang The expanding role of mitochondria in apoptosis [J]. Genes Dev., 15 (2001), pp. 2922-2933.
[3] P. Li, D. Nijhawan, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade [J]. Cell, 91 (1997), pp. 479-489.
[4] Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997, 388 (6639): 300-304.
[5] LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998, 17 (25): 3247-3259.
[6] Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y: Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000, 406 (6798): 855-862.
[7] Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43?3 (2000).
[8] Chai, J. et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406, 855-62 (2000).
[9] Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li YM, Jiang X: A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem. 2007, 282 (42): 30718-30727.
[10] Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y, et al: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001, 410 (6824): 112-116.
[11] Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermohlen O, Heimlich G, Abken H, Kronke M: XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood. 2006, 108 (10): 3434-3440.
[12] Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, Jurgensmeier JM: XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med. 2003, 198 (2): 341-347.

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1